The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity

Amador, Roberto; Moreno, Alberto; Valero, Victoria; Murillo, Luis A.; Mora, Ana L.; Rojas, Mauricio; Rocha, Claudia; Salcedo, Margarita; Guzmán, Fanny; Espejo, Fabiola; Nuñez, F.; Patarroyo, Manuel E.

doi:10.1016/0264-410x(92)90009-9

Cited by 79 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because previous studies with greater numbers of subjects (Ͼ 200 per group) have been unable to determine whether SPf66 reduced the incidence of P. falciparum infection or disease, [5][6][7][8][9][10][11] it is not surprising that this study (with complete data for 69 subjects [21-26 per group]) also failed to resolve that question.…”

Section: Resultsmentioning

confidence: 83%

“…[5][6][7][8][9][10][11] Although there has been no evidence of serious toxicity during these studies, the efficacy of SPf66 has been controversial (ranging from Ϫ9% to ϩ74%).…”

Section: C-g-d-e-l-e-a-e-t-q-n-v-y-a-a-p-n-a-n-p-y-s-l-f-q-k-e-k-m-v-mentioning

confidence: 99%

“…These results suggest that immunization with SPf66 does not produce a selective effect in vivo. They demonstrate a molecular method to test for selection in vivo as an indirect measure of vaccine efficacy.Between one and two million deaths result from falciparum malaria each year, 90% of which occur among children less than five years of age in sub-Saharan Africa.1 In addition, the recent worldwide increase in the morbidity and mortality of malaria caused by drug-resistant Plasmodium falciparum has strengthened the argument for development of a malaria vaccine.2,3 SPf66 is a synthetic peptide vaccine candidate with the following sequence: 4,5 …”

mentioning

confidence: 99%

“…1 In addition, the recent worldwide increase in the morbidity and mortality of malaria caused by drug-resistant Plasmodium falciparum has strengthened the argument for development of a malaria vaccine. 2,3 SPf66 is a synthetic peptide vaccine candidate with the following sequence: 4,5 …”

mentioning

confidence: 99%

See 3 more Smart Citations

Immunization with SPf66 and subsequent infection with homologous and heterologous Plasmodium falciparum parasites.

Masinde¹,

Krogstad²,

Gordon³

et al. 1998

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. In an area of intense transmission, a malaria vaccine could reduce infection due to the parasite types represented in the vaccine, but have no detectable effect on the overall frequency of infection if it did not protect against infection with heterologous parasites. These studies were performed to determine whether immunization with SPf66 decreased infection with homologous parasites containing the 11 amino acid peptide from merozoite surface protein-1 (MSP-1) in SPf66, or increased infection due to heterologous parasites containing heterologous (alternative) MSP-1 sequences. Based on this 11 amino acid peptide (YSLFQKEKMVL), three forward primers (S,Q,V) were designed to amplify the MSP-1 sequence present in SPf66, and 3 additional forward primers (G,H,I) to amplify the alternative MSP-1 sequence (YGLFHKEKMIL). This strategy was validated by polymerase chain reaction (PCR) amplification and dideoxy sequencing with 14 cloned laboratory isolates, which demonstrated that each primer amplified one MSP-1 sequence or the other, but not both. The technique was then used to examine filter paper blots from an SPf66 vaccine study of 69 subjects in Saradidi, Kenya. In that study, the prevalence of infection with YSLFQKEKMVL or YGLFHKEKMIL type parasites was unaffected by immunization with SPf66 (based on PCR amplification with the S, Q, V, G, H and I primers, respectively). These results suggest that immunization with SPf66 does not produce a selective effect in vivo. They demonstrate a molecular method to test for selection in vivo as an indirect measure of vaccine efficacy.Between one and two million deaths result from falciparum malaria each year, 90% of which occur among children less than five years of age in sub-Saharan Africa.1 In addition, the recent worldwide increase in the morbidity and mortality of malaria caused by drug-resistant Plasmodium falciparum has strengthened the argument for development of a malaria vaccine.2,3 SPf66 is a synthetic peptide vaccine candidate with the following sequence: 4,5

show abstract

Section: Resultsmentioning

confidence: 83%

“…[5][6][7][8][9][10][11] Although there has been no evidence of serious toxicity during these studies, the efficacy of SPf66 has been controversial (ranging from Ϫ9% to ϩ74%).…”

Section: C-g-d-e-l-e-a-e-t-q-n-v-y-a-a-p-n-a-n-p-y-s-l-f-q-k-e-k-m-v-mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Immunization with SPf66 and subsequent infection with homologous and heterologous Plasmodium falciparum parasites.

Masinde¹,

Krogstad²,

Gordon³

et al. 1998

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…This vaccine has undergone extensive trial and was found to be safe and immunogenic. 21,22 In Tanzania, it showed protective efficacy in 31% in children aged 1-5 years. 23 However, results from a study in the Gambia failed to demonstrate protection against Malaria in infants of 6-11 months of age.…”

mentioning

confidence: 99%